CCR5 targeted SIV vaccination strategy preventing or inhibiting SIV infection

被引：17

作者：

Bogers, WMJM

Bergmeier, LA

Oostermeijer, H

ten Haaft, P

Wang, Y

Kelly, CG

Singh, M

Heeney, JL

Lehner, T ^{[1
]}

机构：

[1] Guys Kings & St Thomas Hosp Med & Dent Sch, Dept Oral Med & Pathol, Mucosal Immunol Unit, London SE1 9RT, England

[2] Biomed Res Primate Ctr, Dept Virol, Rijswijk, Netherlands

[3] Lionex Diagnost & Therapeut GmbH, Braunschweig, Germany

来源：

VACCINE | 2004年 / 22卷 / 23-24期

关键词：

SIV; vaccine; CCR5;

D O I：

10.1016/j.vaccine.2004.02.050

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cell-surface CCR5 is a major coreceptor with CD4 glycoprotein, mediating cellular entry of CCR5 strains of HIV-1 or SIV We targeted the SIV CCR5 coreceptor in a combined CCR5-SIV antigen immunization strategy. Rhesus macaques were immunized i.m. with the 70 kDa heat shock protein (HSP70) covalently linked to the CCR5 peptides, SIV gp120 and p27. Intravenous challenge with SIVmac 8980 prevented SIV infection or decreased the viral load with the CCR5-SIV combined vaccine. CC chemokines and antibodies which block and downmodulate CCR5 were induced, as well as immune responses to the subunit SIV antigens. This novel vaccination strategy complements cognate immunity to SIV with innate immunity to the CCR5 coreceptor of SIV. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：2974 / 2984

页数：11

共 45 条

[31]

Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO

[32]

2-N

[33] Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes [J].

Sallusto, F ;

Lenig, D ;

Mackay, CR ;

Lanzavecchia, A .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (06) :875-883

[34] Endocytosis and recycling of the HIV coreceptor CCR5 [J].

Signoret, N ;

Pelchen-Matthews, A ;

Mack, M ;

Proudfoot, AEI ;

Marsh, M .

JOURNAL OF CELL BIOLOGY, 2000, 151 (06) :1281-1293

[35] Lack of infection in HIV-exposed individuals is associated with a strong CD8+ cell noncytotoxic anti-HIV response [J].

Stranford, SA ;

Skurnick, J ;

Louria, D ;

Osmond, D ;

Chang, SY ;

Sninsky, J ;

Ferrari, G ;

Weinhold, K ;

Lindquist, C ;

Levy, JA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (03) :1030-1035

[36] A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques [J].

Ten Haaft, P ;

Verstrepen, B ;

Überla, K ;

Rosenwirth, B ;

Heeney, J .

JOURNAL OF VIROLOGY, 1998, 72 (12) :10281-10285

[37] Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage [J].

Trkola, A ;

Ketas, T ;

Kewalramani, VN ;

Endorf, F ;

Binley, JM ;

Katinger, H ;

Robinson, J ;

Littman, DR ;

Moore, JP .

JOURNAL OF VIROLOGY, 1998, 72 (03) :1876-1885

[38] LYMPHOCYTES-CD8+ CAN CONTROL HIV-INFECTION INVITRO BY SUPPRESSING VIRUS-REPLICATION [J].

WALKER, CM ;

MOODY, DJ ;

STITES, DP ;

LEVY, JA .

SCIENCE, 1986, 234 (4783) :1563-1566

[39] Allo-immunization elicits CCR5 antibodies, SDF-1 chemokines, and CD8-suppressor factors that inhibit transmission of R5 and X4 HIV-1 in women [J].

Wang, Y ;

Underwood, J ;

Vaughan, R ;

Harmer, A ;

Doyle, C ;

Lehner, T .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2002, 129 (03) :493-501

[40] Allo-immunization elicits CD8+ T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women [J].

Wang, YF ;

Tao, L ;

Mitchell, E ;

Bravery, C ;

Berlingieri, P ;

Armstrong, P ;

Vaughan, R ;

Underwood, J ;

Lehner, T .

NATURE MEDICINE, 1999, 5 (09) :1004-1009

← 1 2 3 4 5 →